Cochlear implantation in patients with autoimmune hearing loss
CONCLUSION: Cochlear implantation can be necessary in some AIED patients and poses a sufficient method for hearing rehabilitation. Depending on the activity of the underlying disease, a rise in impedances may occur. Immunomodulatory treatment may therefore be necessary to maintain adequate hearing results with the CI.PMID:38647666 | DOI:10.1007/s00106-024-01472-5 (Source: HNO)
Source: HNO - April 22, 2024 Category: ENT & OMF Authors: Maximilian Armstorfer Lennart Weitgasser Stefan Tschani Sebastian R ösch Source Type: research
Baseline Characteristics and mNAPSI Change from Baseline Scores Through Month 12 for Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Nail Psoriasis Treated with Biologics from PSoHO
ConclusionThis real-world study showed that patients with moderate-to-severe psoriasis and any severity of concomitant nail involvement had significantly faster and more substantial improvements in nail psoriasis up to month 6 in the anti-IL-17A cohort compared to the other biologics cohort. Of the individual biologics studied, ixekizumab showed the highest numerical improvements in nail psoriasis at month 12.Trial registrationEUPAS24207. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - April 22, 2024 Category: Dermatology Source Type: research
Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical Trial
ConclusionThis post hoc analysis is supportive of the hypothesis that ixekizumab reduces pain in AS by additional mechanisms other than the reduction of measurable inflammation.Trial Registration NumberNCT02696785. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - April 18, 2024 Category: Rheumatology Source Type: research
Population Pharmacokinetics of Adalimumab in Juvenile Idiopathic Arthritis Patients: A Retrospective Cohort Study Using Clinical Care Data
CONCLUSIONS: Five literature models effectively described adalimumab PK in this pediatric cohort, highlighting the potential for extrapolating existing models to the pediatric population. The new JIA model confirmed the effect of several known covariates and found a novel association for drug clearance with methotrexate use (lower) and uveitis (higher), which might have clinical relevance for personalized dosing in JIA.PMID:38630199 | DOI:10.1007/s40272-024-00629-7 (Source: Paediatric Drugs)
Source: Paediatric Drugs - April 17, 2024 Category: Pediatrics Authors: Amara Nassar-Sheikh Rashid Femke Hooijberg Sandy C Bergkamp Mariken P Gruppen Taco W Kuijpers Mike Nurmohamed Theo Rispens Gertjan Wolbink J Merlijn van den Berg Dieneke Schonenberg-Meinema Ron A A Math ôt Source Type: research
Surgical management of a case of non-resolving bullous retinal detachment due to probable Vogt-Koyanagi-Harada syndrome
Eur J Ophthalmol. 2024 Apr 17:11206721241247582. doi: 10.1177/11206721241247582. Online ahead of print.ABSTRACTA 45-year-old male with Vogt-Koyanagi-Harada (VKH) syndrome presented with vision loss in his right eye after discontinuing treatment during the COVID-19 pandemic. He was found to have bullous retinal detachment (RD) in the right eye and was started on subcutaneous adalimumab with oral corticosteroid following three doses of pulse corticosteroid. But when RD did not resolve after 4 months of treatment and ultrasound B scan showed bullous RD with retino-retinal adhesion, he was planned for surgical intervention. Du...
Source: European Journal of Ophthalmology - April 17, 2024 Category: Opthalmology Authors: Parthopratim Dutta Majumder Mauli Shah Parveen Sen Source Type: research
Population Pharmacokinetics of Adalimumab in Juvenile Idiopathic Arthritis Patients: A Retrospective Cohort Study Using Clinical Care Data
ConclusionsFive literature models effectively described adalimumab PK in this pediatric cohort, highlighting the potential for extrapolating existing models to the pediatric population. The new JIA model confirmed the effect of several known covariates and found a novel association for drug clearance with methotrexate use (lower) and uveitis (higher), which might have clinical relevance for personalized dosing in JIA. (Source: Pediatric Drugs)
Source: Pediatric Drugs - April 17, 2024 Category: Pediatrics Source Type: research
Use of biologics for psoriasis in solid organ transplant recipients
We report a case from our institution of a 29-year-old man with a history of psoriasis, who underwent a kidney transplant and later developed erythroderma. He did not respond to traditional treatments and was successfully treated with adalimumab, leading to the discontinuation of MMF. We also reviewed literature in solid organ transplant patients with psoriasis. Our findings, based on 10 articles, indicate a cautious approach to using biologics in this group, with further research needed for efficacy and safety.PMID:38623950 | DOI:10.1111/ajd.14292 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - April 16, 2024 Category: Dermatology Authors: Marta Costa Blasco Claire Doyle Sophie Diong Siona Ni Raghallaigh Source Type: research
Use of biologics for psoriasis in solid organ transplant recipients
We report a case from our institution of a 29-year-old man with a history of psoriasis, who underwent a kidney transplant and later developed erythroderma. He did not respond to traditional treatments and was successfully treated with adalimumab, leading to the discontinuation of MMF. We also reviewed literature in solid organ transplant patients with psoriasis. Our findings, based on 10 articles, indicate a cautious approach to using biologics in this group, with further research needed for efficacy and safety.PMID:38623950 | DOI:10.1111/ajd.14292 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - April 16, 2024 Category: Dermatology Authors: Marta Costa Blasco Claire Doyle Sophie Diong Siona Ni Raghallaigh Source Type: research
Successful use of adalimumab in treating granuloma faciale resistant to traditional therapies
Australas J Dermatol. 2024 Apr 14. doi: 10.1111/ajd.14260. Online ahead of print.NO ABSTRACTPMID:38616534 | DOI:10.1111/ajd.14260 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - April 15, 2024 Category: Dermatology Authors: Martina Mussi Corrado Zengarini Filippo Viviani Lidia Sacchelli Alessandro Pileri Federico Bardazzi Source Type: research
A rare condition underlying childhood back pain: chronic nonbacterial osteomyelitis
Orv Hetil. 2024 Apr 14;165(15):595-600. doi: 10.1556/650.2024.33021. Print 2024 Apr 14.ABSTRACTA gerincfájdalom hátterében a gyakoribb benignus kórképek mellett malignus elváltozások és súlyos gyulladással jellemezhető kórképek is előfordulhatnak. A kivizsgálás során a részletes laboratóriumi vizsgálatok mellett a képalkotó diagnosztikának kiemelkedő jelentősége van. A csontfájdalom hátterében ritkán a krónikus nem bakteriális osteomyelitis is állhat. A szerzők egy 9 éves leánygyermek esetét mutatják be, aki több hónapja fennálló, progrediáló háti gerincfájdalommal jelentkezett...
Source: Orvosi Hetilap - April 15, 2024 Category: General Medicine Authors: Janka Juszt No émi Benedek Gabriella Mohay Zsuzsanna Herbert Ádám Győri Bernadett Mosd ósi Source Type: research
A rare condition underlying childhood back pain: chronic nonbacterial osteomyelitis
Orv Hetil. 2024 Apr 14;165(15):595-600. doi: 10.1556/650.2024.33021. Print 2024 Apr 14.ABSTRACTA gerincfájdalom hátterében a gyakoribb benignus kórképek mellett malignus elváltozások és súlyos gyulladással jellemezhető kórképek is előfordulhatnak. A kivizsgálás során a részletes laboratóriumi vizsgálatok mellett a képalkotó diagnosztikának kiemelkedő jelentősége van. A csontfájdalom hátterében ritkán a krónikus nem bakteriális osteomyelitis is állhat. A szerzők egy 9 éves leánygyermek esetét mutatják be, aki több hónapja fennálló, progrediáló háti gerincfájdalommal jelentkezett...
Source: Orvosi Hetilap - April 15, 2024 Category: General Medicine Authors: Janka Juszt No émi Benedek Gabriella Mohay Zsuzsanna Herbert Ádám Győri Bernadett Mosd ósi Source Type: research
Adalimumab as treatment for neurosarcoidosis: A case series
Sarcoidosis is a disease characterized by non-caseating granulomas that can involve the central nervous system as neurosarcoidosis. This challenging disease is currently managed with high dose steroids, and sometimes the addition of infliximab. Other TNA-alpha inhibitors have not been studied as rigorously. We discovered ten neurosarcoidosis patients who were on an alternative TNA-alpha inhibitor, adalimumab. Eight patients had a positive response clinically and radiographically to adalimumab. (Source: Journal of the Neurological Sciences)
Source: Journal of the Neurological Sciences - April 15, 2024 Category: Neurology Authors: Jeffrey Shen, Megumi Sugita, Andrea Linares-Lopez, Suma Shah, Christopher Eckstein, Elijah Lackey Tags: Clinical short communication Source Type: research
Switch from adalimumab to brodalumab as a possible trigger factor for the onset of pyoderma gangrenosum
Australas J Dermatol. 2024 Apr 10. doi: 10.1111/ajd.14266. Online ahead of print.NO ABSTRACTPMID:38597123 | DOI:10.1111/ajd.14266 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - April 10, 2024 Category: Dermatology Authors: Giorgia Salvia Matteo Bevilacqua Flavia Manzo Margiotta Alessandra Michelucci Giammarco Granieri Cristian Fidanzi Valentina Dini Marco Romanelli Carlo Mazzatenta Source Type: research
Brodalumab for moderate-severe hidradenitis suppurativa: An open-label multicentric cohort study in real clinical practice
CONCLUSIONS: Brodalumab seems to be effective and safe in patients with moderate to severe HS, even in those that did not respond to adalimumab, which, at the moment, is the only widely approved biologic for this indication. Thus, it stands as an interesting option for the treatment of HS.PMID:38597096 | DOI:10.1111/ajd.14267 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - April 10, 2024 Category: Dermatology Authors: Guiovana Fernanda Osorio-G ómez Juan Ortiz- Álvarez Delia Diaz-Ceca Cesar Guijarro-S ánchez Juli án Conejo-Mir Sánchez Pablo Fern ández Crehuet Source Type: research
Effect of adalimumab as an anti-inflammatory agent on gene expression of retinal pigment epithelial cells
In conclusion, despite its safety, the 2x concentration of ADA was the only dose that did not ignite the expression of any of the studied inflammatory and fibrogenesis genes. This dosage, which is roughly equal to 2 mg intravitreal dose in a clinical setting, might be referred to as a reference starting point for future in-vivo studies in ocular conditions.PMID:38599062 | DOI:10.1016/j.biopha.2024.116568 (Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie)
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 10, 2024 Category: Drugs & Pharmacology Authors: M Hossein Nowroozzadeh Mojtaba Yousefi Mostafa Abuali Fatemeh Sanie-Jahromi Source Type: research
